Completed PHASE4 INTERVENTIONAL 2-arm NCT00404547

Asthma Care With Alvesco® (Ciclesonide) in Primary Care in Adults - The ACCEPT-study (BY9010/CA-102)

An Open-Label Randomized, Multicenter Study in Patients With Asthma to Evaluate the Effectiveness of Alvesco® (Ciclesonide) Compared to Asthma Usual Care in a Primary Practice Setting

Sponsor: AstraZeneca

Conditions Asthma

Interventions Ciclesonide Usual Care Inhaled Glucocorticosteroids

Updated 8 times since 2017 Last updated: Dec 2, 2016 Started: Nov 30, 2006 Primary completion: Apr 30, 2008 Completion: Dec 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Asthma and is currently completed. AstraZeneca leads this study, which shows 8 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Oct 2025 — Present [monthly]

Completed PHASE4
Sep 2025 — Oct 2025 [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Nov 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abbotsford, Canada , Ajax, Canada , Alma, Canada , Anjou, Canada , Barrie, Canada , Brampton, Canada , Brossard, Canada , Burnaby, Canada , Cacouna, Canada , Calgary, Canada and 89 more locations